The notices it replaced
- Reissues: PA-23-230 PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 2 steps back: PA-22-176 PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 3 steps back: PA-21-259 PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 4 steps back: PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 5 steps back: PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed
- 6 steps back: PA-18-574 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 7 steps back: PA-17-302 PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 8 steps back: PA-16-302 PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 9 steps back: PA-15-269 PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 10 steps back: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 11 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 12 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 13 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 14 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 15 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 16 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Who won it before
7,961 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,526,629,860 in first-year total cost, median $299,617.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]284
- Special Emphasis Panel[ZRG1 ETTN-G (12)]236
- Special Emphasis Panel[ZRG1 IMST-H (15)]202
- Special Emphasis Panel[ZRG1 IDM-V (12)]185
- Special Emphasis Panel[ZRG1 IMST-B (12)]179
Most frequent institutions
- EPICYPHER, INC.49
- PHYSICAL SCIENCES, INC48
- AFFINERGY, LLC31
- MINNESOTA HEALTHSOLUTIONS CORPORATION31
- LYNNTECH, INC.29
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | A Safe, Fast, and Cost-Effective System for Tissue Removal in Laparoscopic Hysterectomy and Other Minimally Invasive Surgery2R44HD105575-03 | FRANCIS, DANIEL | CLARIA MEDICAL, INC., CA | $2,138,797 | ZHD1 |
| 2025 | Proof of concept and dose response of CAM-6019 for HFrEF patients1R44HL182393-01 | UMANSKY, KFIR | VELAKOR BIOTHERAPEUTICS, INC., NY | $2,095,748 | ZHL1 |
| 2025 | Improved Treatment Options for Vertebral Compression Fractures in Elderly Patients Using Minimally Invasive, Image-Guided Delivery of a Regenerative Bone Adhesive1R44AG097243-01 | MCDONOUGH, BRITTANY | REVBIO, INC., MA | $2,040,626 | ZAG1 |
| 2025 | Assay development for the assessment of pregnancy risks in early pregnancy2R44EB033715-02 · under PA-23-230 | ARMANT, DAVID RANDALLDREWLO, SASCHA | AKNA HEALTH LLC, MI | $1,949,879 | ZRG1 |
| 2025 | A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis2R44AR083730-02A1 | TUBAU-JUNI, NURIA | BIOTHERAPEUTICS, INC., VA | $1,854,342 | ZAR1 |
| 2025 | IntelliStent: A minimally Invasive, Adjustable Pulmonary Flow Restrictor System for Congenital and Acquired Heart Disease1R44HL182590-01 | AMIN, ELENABOGNER, SETH ADAM | HEARTPOINT GLOBAL INC, FL | $1,771,084 | ZHL1 |
| 2025 | Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant2R44HL158313-02A1 | ELSER, JEREMY A | SHIP OF THESEUS, LLC, PA | $1,770,171 | ZHL1 |
| 2025 | Scaling Lymphoma Diagnosis: A Cost-Effective Gene Expression Assay for Broad Implementation1R44CA310364-01 | BRIERCHECK, EDWARDGUYON, TIMOTHY | RAIZ DIAGNOSTICS, INC., MA | $1,770,000 | ZRG1 |
| 2025 | Deep Learning Serial Radiomics for Improved Cancer Therapy Response Assessment.1R44CA302212-01 | SCHMIDT, TALY GILAT | ONC.AI, INC., CA | $1,686,258 | ZRG1 |
| 2025 | Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes1R44GM158472-01 · under PA-23-230 | HUANG, CHARLIE | SYNVIVIA, INC., CA | $1,640,169 | ZRG1 |
| 2025 | Drug development of RK-33 for breast cancer treatment1R44CA295155-01A1 | VENTURA, DOMINIC AVESUNA, FARHAD | NATSAR PHARMACEUTICALS, INC., MD | $1,634,811 | ZRG1 |
| 2025 | eiF2B Activators to Treat Noise-Induced Hearing Loss2R44DC020069-02A1 · under PA-23-230 | CHOUCHANE, MALEKDAHL, RUSSELL | JACARANDA BIOSCIENCES, INC., CA | $1,554,254 | ZRG1 |
| 2025 | Non-Contact Point of Care Device for Sleep Studies2R44AG060779-04A1 | CONDON, JOHN PAUL | INNOVATIVE DESIGN LABS, INC., MN | $1,546,575 | ZAG1 |
| 2025 | Deep learning image classification model for pediatric ear disease1R44EB036883-01A1 | HILL, COURTNEY | GLIMPSE DIAGNOSTICS, INC., MN | $1,535,084 | ZRG1 |
| 2025 | Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme1R44NS141514-01A1 | ACOSTA, WALTERCRAMER, CAROLE L.YANG, TIANHONG | BIOSTRATEGIES, LC, AR | $1,500,000 | ZRG1 |
| 2025 | Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced Dementia2R44AG071386-03A1 | HICKMAN, JAMES JTURGEON, JACQUES | HESPEROS, LLC, FL | $1,500,000 | ZRG1 |
| 2025 | Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)1R44NS137896-01A1 | LISTON, THEODORE E | ASTROCYTE PHARMACEUTICALS, INC., MA | $1,499,886 | ZRG1 |
| 2025 | Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy1R44NS143576-01 | CERNE, ROK | RESPIRERX PHARMACEUTICALS INC., NJ | $1,499,869 | ZRG1 |
| 2025 | Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I1R44NS143501-01 | MCCARTY, DOUGLAS M | NEUROGT, INC., NC | $1,499,504 | ZRG1 |
| 2025 | Development of a novel oral brain penetrant therapeutic for ALS disease1R44NS141531-01A1 | LARSEN, GLENNWOLOZIN, BENJAMIN L | AQUINNAH PHARMACEUTICALS, INC., MA | $1,499,212 | ZRG1 |
| 2025 | Engineered microglia for the treatment of Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)1R44NS139748-01A1 | GANDHI, SUNIL | SAVANNA BIOTHERAPEUTICS, INC., CA | $1,489,811 | ZRG1 |
| 2025 | Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.2R44HL160338-02 · under PA-23-230 | ARGENTIERI, THOMASYOUNG, LINDON H | YOUNG THERAPEUTICS, LLC, PA | $1,488,899 | ZRG1 |
| 2025 | Extended-release injectable gel for multi-day treatment of postoperative pain2R44GM145020-02 · under PA-23-230 | OVERSTREET, DEREK JAMES | SONORAN BIOSCIENCES, INC., AZ | $1,479,276 | ZRG1 |
| 2025 | Development of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris2R44AR082722-02A1 | LIU, OLIVER WEI | TOPAZ BIOSCIENCES, INC., CA | $1,469,201 | ZRG1 |
| 2025 | Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines2R44GM146506-02 | ANSELMO, AARON C | VITAKEY, INC., DC | $1,437,278 | ZGM1 |
| 2025 | pan-XLSM: an AI-powered microscopy platform for imaging and analysis of highly expanded tissue samples1R44GM159519-01 | M'SAAD, ONS | PANLUMINATE INC., CT | $1,416,590 | ZRG1 |
| 2025 | Point of Care Detection of HPV and P16 in Saliva2R44DE033312-02 | KHOSRAVI-FAR, ROYA | INNOTECH PRECISION MEDICINE, INC, MA | $1,414,853 | ZRG1 |
| 2025 | Brain-Wide Quantification of Blood-Brain Barrier Penetrating Antibody Therapeutics1R44AG090130-01A1 | WHEELER, DAMIAN G. | TRANSLUCENCE BIOSYSTEMS, INC., CA | $1,400,651 | ZRG1 |
| 2025 | Low Cost Carbon Dioxide-Based Cryoablation for Breast Cancer Treatment in Low Resource Settings2R44CA261360-02A1 | SURTEES, BAILEY | KUBANDA CRYOTHERAPY, INC., MD | $1,399,357 | ZRG1 |
| 2025 | Development of a topical tracer to detect TDP43 in ALS, LATE and FTD retinas for AI-powered disease insights2R44AG078075-02 | SARRAF, STELLA | AMYDIS DIAGNOSTICS, INC., CA | $1,388,697 | ZRG1 |
| 2025 | Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts2R44AG084351-02 · under PA-23-230 | CRAVENS, AARON | REVEL PHARMACEUTICALS INC., CA | $1,364,162 | ZRG1 |
| 2025 | Revolutionizing CAR T-cell Therapy: Enhancing Activity and Persistence of CAR T-cell by Developing a CAR-Enhancer Platform1R44CA298774-01A1 | MAHINI, HAMID | KOI BIOTHERAPEUTICS INC., DE | $1,340,987 | ZRG1 |
| 2025 | Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults1R44AG092210-01A1 | NEELAKANTAN, HARSHINI | RIDGELINE THERAPEUTICS, LLC, TX | $1,339,717 | ZAG1 |
| 2025 | The Development of Tabletop Brain-Mapping Platform2R44MH129132-03 · under PA-23-230 | RAGAN, TIMOTHY M. | TISSUEVISION, INC., MA | $1,335,696 | ZRG1 |
| 2025 | Reducing structural damage and adverse surgical events during cochlear implantation using an intraoperative sensing system2R44DC021397-02 | REDDY, JAY W | ADVANCED OPTRONICS, INC., PA | $1,297,496 | ZDC1 |
| 2025 | Novel wearable rotating magnetic field therapy device targeting treatment of brain cancers1R44CA302219-01 | GOWDA, ASHOK | BIOTEX, INC., TX | $1,296,385 | ZRG1 |
| 2025 | A novel agent for preventing fatty degeneration of muscles in LGMD2B2R44AR081168-02 · under PA-23-230 | FLOER, MONIQUE | ADVERTENT BIOTHERAPEUTICS, INC., MI | $1,292,847 | ZRG1 |
| 2025 | Heart Muscle Regeneration1R44HL180034-01A1 | BRAR, BHAWANJIT KPETERSON, KIRK | JAAN BIOTHERAPEUTICS, INC., CA | $1,290,338 | ZHL1 |
| 2025 | Analysis of Cutaneous Phosphorylated alpha-Synuclein to Identify Patients at Risk of Progressing from Essential Tremor to Parkinson's Disease1R44NS143486-01 | GIBBONS, CHRISTOPHER H | CND LIFE SCIENCES, INC., AZ | $1,276,662 | ZRG1 |
| 2025 | A Commercial Platform for High-Volume Behavior and Electrophysiology Research1R44MH142264-01 | FRANK, LOREN MKARLSSON, MATTIAS PETER | SPIKEGADGETS, LLC, CA | $1,266,318 | ZMH1 |
| 2025 | Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options2R44HG013456-02 · under PA-23-230 | SCHERER, ANDREAS | GOLDEN HELIX, INC., MT | $1,264,651 | ZRG1 |
| 2025 | Asymmetric nucleosome substrates to advance the study of the histone code1R44GM154510-01A1 | BURG, JONATHAN MICHAELCHEEK, MARCUS | EPICYPHER, INC., NC | $1,264,176 | ZGM1 |
| 2025 | Human iPSC neural spheroids to screen for compounds that block tau propagation1R44AG097355-01 | FREMEAU, ROBERT TREES, STEVEN DSTILES, TRAVIS LEE | NOVORON BIOSCIENCE, INC., CA | $1,257,528 | ZAG1 |
| 2025 | AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannoma1R44NS145814-01 | YANG, NA NORA | MERLIN THERAPEUTICS INC, PA | $1,256,291 | ZNS1 |
| 2025 | Next generation spatial genomics tools for the human brain1R44MH140731-01 | FRIEDA, KIRSTEN | SPATIAL GENOMICS, INC., CA | $1,244,076 | ZRG1 |
| 2025 | A unified eligibility application and determination system to increase Ryan White linkage to care and retention in care by reducing structural barriers and facilitating client engagement1R44MH136864-01A1 · under PA-23-230 | HEDGCOCK, BOB HARRISON | GROUPWARE TECHNOLOGIES, LLC, WI | $1,243,071 | ZRG1 |
| 2025 | Phase II- Repurposing CRH antagonists for the treatment of endometriosis2R44HD109055-02A1 | APPLEYARD, CAROLINE BTORRES-REVERON, ANNELYN | SUR180 THERAPEUTICS, LLC, TX | $1,239,987 | ZRG1 |
| 2025 | A Novel Instrument and Consumables for Quality Control in Next Generation Sequencing1R44HG014079-01 · under PA-23-230 | REED, JASON C | EVIZIA INC, VA | $1,234,692 | ZRG1 |
| 2025 | Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer1R44CA298532-01A1 | JAILKHANI, NOORZIMMERMANN, DENNIS | MATRISOME BIO, INC., MA | $1,233,778 | ZCA1 |
| 2025 | Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma1R44CA298512-01 · under PA-23-230 | COOPER, COLLEEN DOYLE | CELDARA MEDICAL, LLC, NH | $1,228,902 | ZRG1 |
| 2025 | TissueReM: Whole-Organism, Real-time Decision-enabled 3D Tissue Imaging and Recovery for Molecular Analysis2R44GM145205-02 · under PA-23-230 | BRADY-KALNAY, SUSANN MGARGESHA, MADHUSUDHANA | BIOINVISION, INC., OH | $1,221,189 | ZRG1 |
| 2025 | High-flow portable oxygen concentrator for long-term oxygen therapy1R44HL178137-01A1 | DICKERHOFF, BENJAMIN ROBERTMUBEEN, SYEDRAGHAVAN, MADHAVAN L | PRANIONS, INC., IA | $1,213,182 | ZRG1 |
| 2025 | Validation of next-generation TMS system optimizing for widely scalable, personalized treatment of depression1R44MH136880-01A1 · under PA-23-230 | DOWNAR, JONATHAN ALEXANDER STEWART | AMPA INC., CA | $1,199,261 | ZRG1 |
| 2025 | MR^3: Development of a Molecular Rotational Resonance Ratiometer1R44GM157779-01A1 | SHIPMAN, STEVE | BRIGHTSPEC, INC., VA | $1,194,805 | ZRG1 |
| 2025 | Xbeads: A Platform for Flow Cytometry Sample QC and Harmonization2R44GM146557-02 | KRUTZIK, PETER | CYTORUM, INC., CA | $1,178,776 | ZRG1 |
| 2025 | AI-linked cytomics-on-a-chip to enable near-real time identification and management of oral lichenoid lesions in primary care1R44DE033934-01 · under PA-23-230 | CHRISTODOULIDES, NICOLAOS JOSEPHMCDEVITT, JOHN T | ORALIVA, INC., FL | $1,178,476 | ZRG1 |
| 2025 | Advanced Imaging Methods in Pulse EPR1R44CA302113-01A1 | EPEL, BORISKOTECHA, MRIGNAYANIPAGEL, MARK DAVID | O2M TECHNOLOGIES, LLC, IL | $1,164,814 | ZRG1 |
| 2025 | Targeting pancreatic cancer metastases with Targefrin2R44CA277917-02 | BAGGIO, CARLO | ARMIDA LABS, INC., CA | $1,162,000 | ZCA1 |
| 2025 | VIPCare: Virtual Predictive Care workflow with EHR integrated surveillance for optimalfollow-up care management for Cancer Patients2R44CA281547-02A1 | BAGCHI, SUGATO | VIZLITICS INC., NY | $1,154,996 | ZRG1 |
| 2025 | Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke1R44NS145848-01 | ZARIN, PAYAM | GENTIBIO, INC., MA | $1,150,417 | ZNS1 |
| 2025 | Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors1R44CA302066-01 | SCHULTZ, KENNETH | TRETHERA CORPORATION, CA | $1,150,000 | ZRG1 |
| 2025 | Pseudouridine detection with single-base resolution in a multiplexed epitranscriptomics assay1R44GM159469-01 | MILES, ZACHARYSTENGEL, GUDRUN | ALIDA BIOSCIENCES, INC., CA | $1,146,785 | ZRG1 |
| 2025 | SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma1R44CA310402-01 | YANG, MING | MUCOMMUNE, LLC, NC | $1,146,618 | ZRG1 |
| 2025 | DBS-Expert Pro: Automated Deep Brain Stimulation Programming Using Functional Mapping1R44NS143484-01A1 | HELDMAN, DUSTIN A. | GREAT LAKES NEUROTECHNOLOGIES, OH | $1,134,607 | ZNS1 |
| 2025 | Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception1R44HD118898-01 | KUSHIRO, KEIICHIRO | MUCOMMUNE, LLC, NC | $1,130,880 | ZRG1 |
| 2025 | Development of a novel, non-hormonal female contraceptive device to submit IDE2R44HD111106-02 | MAN, EMILY | VENOVA TECHNOLOGIES, INC., MA | $1,125,480 | ZRG1 |
| 2025 | Improving Speed and Cost of Entry for Holographic Optogenetics2R44MH111463-04 · under PA-23-230 | HOY, CHRISTOPHER LUK | MEADOWLARK OPTICS, INC., CO | $1,120,423 | ZRG1 |
| 2025 | Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome2R44TR003744-02A1 · under PA-23-230 | NICHOLS, DYLAN | BIOMESENSE, INC., IL | $1,117,161 | ZRG1 |
| 2025 | Development of a novel visualization, labeling, and tracking engine for human anatomy.2R44CA285081-02A1 | MOLENDA, MATTHEW ALEXANDER | AM OPERATING LLC, OH | $1,116,368 | ZRG1 |
| 2025 | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.2R44CA265512-02A1 | RAMIREZ, CRAIG PATRICK | TEZCAT BIOSCIENCES, INC., CT | $1,113,257 | ZRG1 |
| 2025 | Scanner Agnostic Image-Guided Biopsy Platform Employing Advanced Computer Vision and Computer Graphics to Enable Non-Invasive Registration and Dynamic Projection Mapping1R44CA310355-01 | HU, JAMES | ILLUMINANT SURGICAL, INC., CA | $1,107,943 | ZRG1 |
| 2025 | Development of Deep Learning Tools for Widely-Available, Inexpensive Diagnosis of Coronary Microvascular and Vasomotor Dysfunction1R44HL178315-01 · under PA-23-230 | MOODY, JONATHAN BRYAN | INVIA, LLC, MI | $1,107,749 | ZRG1 |
| 2025 | Improving Rural Access to Pediatric Health Care with Accurate Telehealth Diagnosis of Acute Otitis Media via Wide Scale Use of Smartphone Acoustic Reflectometry2R44MD018225-03A1 | REIDER, JACOBSTOLL, ARNA IONESCU | WAVELY DIAGNOSTICS, INC., WA | $1,104,026 | ZMD1 |
| 2025 | Development of a novel MYC inhibitor for cancer therapy1R44CA302283-01A1 | VOLLRATH, BEN | VORTEX THERAPEUTICS INC, IL | $1,102,729 | ZCA1 |
| 2025 | Novel AMPK activator for treatment of congenital X-linked nephrogenic diabetes insipidus in pediatric patients2R44DK127798-02 | SANDS, JEFF M | NEPHRODI THERAPEUTICS, INC., WA | $1,096,928 | ZRG1 |
| 2025 | CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry1R44CA306491-01 | MCFARLAND, JESSE MISCHAMEJIA ONETO, JOSE M | SHASQI, INC., CA | $1,094,189 | ZCA1 |
| 2025 | Advanced Pre-Clinical Development of O2LineTM System for Type 1 Diabetes Cell Therapy1R44DK142496-01A1 | TEMPELMAN, LINDA ANN | PERSISTA BIO INC, NY | $1,093,967 | ZDK1 |
| 2025 | Scaling a network of small community-based care homes as a high-value alternative to institutional care1R44AG097298-01 | NIKORE, VIPAN | HOMECARE HUB US INC, IL | $1,089,329 | ZAG1 |
| 2025 | High-resolution extended-depth phase-engineered objectives to accelerate spatial 'omics R&D through computational optics2R44GM151926-02 · under PA-23-230 | GAUMER, SCOTT | DOUBLE HELIX OPTICS INC., CO | $1,084,722 | ZRG1 |
| 2025 | Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids1R44TR005339-01A1 · under PA-23-230 | HE, HONGZHANG | CAPTIS DIAGNOSTICS, PA | $1,077,369 | ZRG1 |
| 2025 | Deep-UV Microscopy for Real-Time Adequacy Analysis of Bone Marrow Aspirates2R44EB035057-02 · under PA-23-230 | POWLESS, AMY J | CELLIA SCIENCE, INC., AR | $1,074,143 | ZRG1 |
| 2025 | Reduced Traumatic Lumbar Puncture Rates in Pediatric Oncology Patients Through Development of an AI-Assisted, Ultrasound-Based Interventional Guidance Platform1R44CA302033-01 | MAULDIN, FRANK WILLIAM | RIVANNA MEDICAL, INC., VA | $1,073,736 | ZRG1 |
| 2025 | High-Throughput Western Blotting2R44GM148112-02A1 | BIRTWISTLE, MARC R.ZADEH, CAMERON ORROD | BLOTTING INNOVATIONS, INC, SC | $1,069,263 | ZRG1 |
| 2025 | A Wearable Sensor Platform for Remote Monitoring of Motor Impairment in Huntingtons Disease and Prodromal Huntingtons Disease1R44TR005381-01A1 | ADAMS, JAMIE LYNNVAZIRI, ASHKAN | BIOSENSICS, LLC, MA | $1,064,194 | ZRG1 |
| 2025 | A Precisely Controllable Loss-of-Function Mutation Collection in Drosophila1R44GM161181-01 | TAN, YING | GENETIVISION CORPORATION, TX | $1,061,192 | ZGM1 |
| 2025 | Device Automation of an FDA-cleared CD-Microfluidic Platform for Rapid Tissue Microsizing2R44TR004975-02A1 | ZOBI, AHMED NABIL | SYNTR HEALTH TECHNOLOGIES, LLC, CA | $1,050,276 | ZTR1 |
| 2025 | NanoDiscs for Immune Modulation in Celiac Disease1R44AI192013-01 | DANIEL, WESTON | EVOQ THERAPEUTICS, INC., MI | $1,050,000 | ZRG1 |
| 2025 | An Open Web Service For Fragment-based Design of Small Molecule Inhibitors2R44GM109549-04 | KULP III, JOHN LAURENCE | CONIFER POINT PHARMACEUTICALS, LLC, PA | $1,050,000 | ZRG1 |
| 2025 | Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds2R44AI143079-02 | MEHTA, MANAV | GEL4MED, INC., MA | $1,050,000 | ZRG1 |
| 2025 | Lateral Flow-Electrochemiluminescent (LF-ECL) Test Strips and Portable Reader for Ultrasensitive Foodborne Pathogen Detection2R44CK000679-02A1 | BRUNO, JOHN | NANOHMICS, INC., TX | $1,047,807 | ZRG1 |
| 2025 | Epigenomic analysis of cell-free nucleosomes for cancer research2R44CA284973-02 | JOHNSTONE, ANDREA LYNNVENTERS, BRYAN J | EPICYPHER, INC., NC | $1,047,610 | ZRG1 |
| 2025 | KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain1R44HL178153-01 · under PA-23-230 | NAYLOR, STEPHEN | RENEUROGEN, LLC, WI | $1,045,688 | ZRG1 |
| 2025 | Regeneration of radiation-damaged salivary glands using neurogenicstimulation of stem cells1R44DE033938-01A1 | BAHNEY, TIM | HYDRONOVO, INC, CO | $1,039,386 | ZRG1 |
| 2025 | Low-Cost Amperometric Ozone Monitor for Communities Affected by Wildfires2R44ES033890-02 | WEBER, ANDREW | GINER, INC., MA | $1,036,179 | ZRG1 |
| 2025 | SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy1R44CA306674-01 | YANG, MING | MUCOMMUNE, LLC, NC | $1,031,566 | ZCA1 |
| 2025 | Fundamental Training for Formal and Informal STEM Mentors2R44GM137663-02 · under PA-23-230 | STELTER, REBECCA LYNNSTUMP, KATHRYN N | INNOVATION RESEARCH AND TRAINING, INC., NC | $1,029,219 | ZRG1 |
| 2025 | Microheart muscle based discovery and development of inotropic compounds2R44TR004250-03A1 | WALL, SAMUEL | ORGANOS, INC., CA | $1,029,043 | ZTR1 |
| 2025 | Functionalized Multi-Modal Tetrode Arrays for Real-Time, Site-Specific Neurochemical Monitoring2R44MH134669-02 | JOHNSON, DAVID A | PINNACLE TECHNOLOGY, INC, KS | $1,028,331 | ZRG1 |
| 2025 | An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation2R44AA029642-02 · under PA-23-230 | MANCHEM, PRASAD | PLEIOGENIX INC., CA | $1,025,643 | ZRG1 |
| 2025 | IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis1R44AI192170-01 | KUSHIRO, KEIICHIRO | MUCOMMUNE, LLC, NC | $1,025,000 | ZRG1 |
| 2025 | Development of IMYX-3 for the Treatment of Ulcerative Colitis1R44DK145292-01 | ENG, CHRISTINA | IMMUNYX PHARMA USA INC., NY | $1,024,862 | ZDK1 |
| 2025 | Metrifonate local application for DFU treatment1R44DK141401-01A1 | TEPPER, MARK ALLAN | EPOULOSIS THERAPEUTICS, INC., MA | $1,024,812 | ZRG1 |
| 2025 | Development of a Totally Implanted Left Ventricular Assist Device1R44HL177945-01 · under PA-23-230 | ABER, GREG | CORVION, INC., TX | $1,024,635 | ZRG1 |
| 2025 | XoLacta: An Adjuvant Therapy for treatment of Radiation Side effects during HER2-Positive Breast Cancer Treatment2R44CA272078-02 | MARSH, SPENCER REID | TINY CARGO COMPANY, THE, VA | $1,022,907 | ZCA1 |
| 2025 | Validation of Duoseq as a Genomic Swiss Army Knife for the Diagnosis of Lymphomas2R44CA298055-02 | DAVE, SANDEEPHAPP, LANIE ELIZABETH | DATA DRIVEN BIOSCIENCE INC, NC | $1,022,841 | ZRG1 |
| 2025 | Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer1R44CA291285-01A1 · under PA-23-230 | NJAR, VINCENT COLLINS OFUKARAMAMURTHY, VIDYA P | ISOPRENE PHARMACEUTICALS, INC., MD | $1,022,522 | ZRG1 |
| 2025 | Addressing Challenges in Peripheral Intravenous Catheter Education1R44MD020606-01 | CONDON, JOHN PAUL | INNOVATIVE DESIGN LABS, INC., MN | $1,022,341 | ZRG1 |
| 2025 | Development of novel therapeutics for obesity and type 2 diabetes1R44DK142200-01 · under PA-23-230 | ADAMS, CHRISTOPHER MEBERT, SCOTT MATTHEWMATVEYENKO, ALEKSEY VTALLEY, JOHN JEFFREY | EMMYON, INC., MN | $1,021,719 | ZRG1 |
| 2025 | Development of an effective, low-cost, point-of-care early detection test for oral cancer in low resource settings1R44CA298389-01 · under PA-23-230 | CALIFANO, JOSEPH ACHEN, XI STEVENFRANZMANN, ELIZABETH J | VIGILANT LABORATORIES LLC, FL | $1,021,347 | ZRG1 |
| 2025 | Developing a New Nucleic Acid Extraction Technology to Enable High Quality DNA Sequencing for Formalin Fixed Paraffin Embedded Tissue Samples1R44HG014445-01 | ASTIER, YANN | VELLUM BIOTECHNOLOGY, INC., CA | $1,020,280 | ZRG1 |
| 2025 | Preparation of sequencing libraries for multi-analyte analysis of RNAs2R44HG013284-02A1 | KAZAKOV, SERGEI A | REALSEQ BIOSCIENCES, INC., CA | $1,020,220 | ZRG1 |
| 2025 | Fluorescence-solid phase Extraction (F-SPE) Microfluidic Platform for Rapid, Onsite Detection and Identification of PFAS with Machine Learning2R44ES035349-02A1 | BECK, JASON GREGORYPORTER, MARC DSANT, HIMANSHU | ESPIRA, INC., UT | $1,020,000 | ZRG1 |
| 2025 | Novel approaches for the treatment of autoimmune disease2R44AI174502-02A1 · under PA-23-230 | KANNANGANAT SIDHARTHAN, SUNIL | ASTERO ERADO INC, TX | $1,019,657 | ZRG1 |
| 2025 | REMIT (Rescue Mitochondrial Therapeutics): Unlocking Broad-Spectrum Mitochondrial Rescuers1R44GM161192-01 | PERLSTEIN, ETHAN | PERLARA, PBC, CA | $1,016,229 | ZGM1 |
| 2025 | srvc-EHSR: Sysrev Version Control - Environmental and Health Related Systematic Reviews2R44ES035359-02 | LUECHTEFELD, THOMAS | INSILICA, LLC, MD | $1,014,776 | ZRG1 |
| 2025 | Efficacy of MeniscoFix for Sub-Total Meniscal Replacement: A Comprehensive Approach in Cadaver Knees and an Ovine Surgical Model2R44AR081745-02A1 | WEADOCK, KEVIN S | NOVOPEDICS, INC., NJ | $1,013,912 | ZRG1 |
| 2025 | Development of IN-003PI as passive immunization against human metapneumovirus infection1R44AI191921-01A1 | HUTCHINS, JEFF T | INHALON BIOPHARMA, INC., NC | $1,013,468 | ZAI1 |
| 2025 | IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A1R44AI188967-01A1 | HUTCHINS, JEFF T | INHALON BIOPHARMA, INC., NC | $1,013,003 | ZRG1 |
| 2025 | A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomy1R44EY038138-01 | WILLIAMS, TERE M. | DUB THERAPEUTICS INC., NY | $1,009,285 | ZEY1 |
| 2025 | Developing and Evaluating Visual, Auditory, and Tactile and Text Digital Thematic Map Viewer to Provide Blind and Low Vision Individuals Full Access to Thematic Maps for the First Time1R44EY036316-01A1 · under PA-23-230 | BIGGS, BRANDON | XR NAVIGATION INC., CA | $1,009,268 | ZRG1 |
| 2025 | AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy1R44AI186871-01A1 | NOTTON, TIMOTHYWEINBERGER, ARIEL | AUTONOMOUS THERAPEUTICS, INC., MD | $1,004,473 | ZAI1 |
| 2025 | Cloud/Web-Based Platform for Quantitative SPECT Reconstruction of Therapeutic Radionuclides1R44CA291419-01A1 · under PA-23-230 | FREY, ERIC C.GHALY, MICHAEL | RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC, MD | $1,003,173 | ZRG1 |
| 2025 | A first-in-class product for the clearance of high-risk human papillomaviruses1R44AI188623-01 · under PA-23-230 | THURMAN, ANDREA RIES | DARE BIOSCIENCE, INC., CA | $1,000,000 | ZRG1 |
| 2025 | Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients1R44AI184225-01A1 · under PA-23-230 | STASKO, NATHAN ALLAN | VAST THERAPEUTICS, INC., NC | $1,000,000 | ZRG1 |
| 2025 | Using Targeted, Controlled High Frequency Energy for Treatment of Onychomycosis1R44AI188772-01 · under PA-23-230 | KING, LAURASCHEFELKER, RICHARD WILLIAM | BIACURE THERAPIES, INC., WI | $1,000,000 | ZRG1 |
| 2025 | Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail1R44AI188855-01 · under PA-23-230 | YEN, MINMIN | PHAGEPRO, INC., MA | $1,000,000 | ZRG1 |
| 2025 | An intravascular Bioartificial Pancreas (iBAP)2R44DK104299-04 · under PA-23-230 | BLAHA, CHARLES | SILICON KIDNEY, LLC, CA | $1,000,000 | ZRG1 |
| 2025 | Nebulized ALX1 as a Treatment for Difficult Non-tuberculous Mycobacterial Lung Infections1R44AI186617-01A1 | STASKO, NATHAN ALLAN | VAST THERAPEUTICS, INC., NC | $1,000,000 | ZRG1 |
| 2025 | Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.1R44AI191886-01 | PARHI, AJIT K | TAXIS PHARMACEUTICALS, INC., NJ | $1,000,000 | ZRG1 |
| 2025 | Scaling function-first antibody discovery leveraging memory B cells1R44AI193415-01 | DE RUTTE, JOSEPH | PARTILLION BIOSCIENCE CORPORATION, CA | $1,000,000 | ZRG1 |
| 2025 | A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections2R44AI167078-03A1 | HARDING, CHRISTIAN | VAXNEWMO, LLC, MO | $1,000,000 | ZAI1 |
| 2025 | Multispray Technology for Studying Biomolecular Interactions1R44GM161156-01 | WANG, DAOJING | NEWOMICS, INC, CA | $1,000,000 | ZGM1 |
| 2025 | Sequence-based RNA Fluorescence Assay to Measure Latent HIV Reservoirs2R44AI155075-04A1 | HUIE, JANET L | JAN BIOTECH, INC., NY | $1,000,000 | ZAI1 |
| 2025 | A Two-Tier Effect-Based Water Bioactivity Surveillance System.1R44ES038062-01 | MAKAROV, SERGEI SOBERLIES, NICHOLAS H. | ATTAGENE, INC., NC | $999,999 | ZES1 |
| 2025 | Optimizing SIV reservoir depletion by Tendel bsAb-981R44AI192249-01A1 | SPARGER, ELLEN ELIZABETH | TENDEL THERAPIES INC., CA | $999,991 | ZAI1 |
| 2025 | Air Plasma Sterilization Device with Plasma-in-Lumen Technology2R44FD007709-02 · under PA-23-230 | AGARWAL, PRAWAL | ADVANCED COOLING TECHNOLOGIES, INC., PA | $999,890 | ZRG1 |
| 2025 | IND-enabling studies of D6PV- a novel ApoC-II peptide mimetic therapeutic2R44DK135188-03A1 | DEVALARAJA, MATT | PROTEAN BIO INC., MA | $999,776 | ZRG1 |
| 2025 | OvaReady: An automated microfluidic oocyte retrieval and denudation device2R44HD105529-04 · under PA-23-230 | OZKUMUR, ISMAIL EMRE | AUTOIVF, INC., MA | $997,028 | ZRG1 |
| 2025 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus1R44AI188587-01A1 | SCHULTZ, KENNETH | TRETHERA CORPORATION, CA | $994,978 | ZAI1 |
| 2025 | Providing GMP-grade Terbium-161 as a therapeutic option for US academic institution1R44CA295134-01A1 | HORVATH, IANPIROVANO, GIACOMO M | FUSION ENERGY SOLUTIONS, INC. D/B/A SERVA ENERGY, AZ | $994,810 | ZRG1 |
| 2025 | A novel remote blood separation device for at-home plasma collection for HIV-1 testing2R44PS005271-02 | JAIME, MARIA DE LOS ANGELES | LO BIOSCIENCES, INC., MD | $994,658 | ZRG1 |
| 2025 | Novel, low corrosion, bio-compatible disinfectant with biofilm and residual efficacy2R44AI155114-04 | NKEMNGONG, CARINE | HALOMINE, INC., NY | $991,808 | ZAI1 |
| 2025 | IND-Enabling Development of HIV Maturation Inhibitors Formulated for use as either Oral or Long-Acting Parenterally Administered Agents2R44AI155312-04A1 | WILD, CARL | DFH PHARMA, INC., MD | $986,894 | ZAI1 |
| 2025 | Refinement of a Digital Monitoring System to Reduce Risk of Hospital Acquired Pressure Injuries2R44NR019556-02A1 | SABALKA, LUCAS | OCUVERA LLC, NE | $985,839 | ZRG1 |
| 2025 | IntellipulseTM Platform Technology for Effective Delivery of Therapeutic Agents1R44CA298522-01 · under PA-23-230 | STRANGE, GARY | EF THERAPEUTICS CORP., FL | $984,830 | ZRG1 |
| 2025 | Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials2R44GM148111-02 · under PA-23-230 | DOTY, FRANCIS DAVID | DOTY SCIENTIFIC, INC., SC | $982,970 | ZRG1 |
| 2025 | ENT-based Approach to Cervical Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea1R44HL178050-01 · under PA-23-230 | GELFAND, MARK | CORIDEA, LLC, NY | $982,086 | ZRG1 |
| 2025 | TulleKit: Integrated Deep Brain Neural Recording System for Non-Human Primate Models1R44MH142259-01 | NOVELLO, JOSEPHZIMMERMANN, JAN | NEURALTHREAD INC, CA | $980,661 | ZMH1 |
| 2025 | Development of Cobinamide as a Cyanide Antidote: Completion of pre-IND Studies1R44AI191943-01 | BOSS, GERRY RDRETCHEN, KENNETH | MESA SCIENCE ASSOCIATES, INC., MD | $980,358 | ZRG1 |
| 2025 | Multivariate machine learning analysis of blood-based RNA expression profiles to distinguish relapsing-remitting and progressive forms of multiple sclerosis1R44AI195280-01 | SPURLOCK, CHARLES FLOYD | DECODE HEALTH, INC., TN | $979,138 | ZAI1 |
| 2025 | Peptide-based ELISA for laboratory diagnosis of sarcoidosis1R44HL180181-01 | LEVIN, ANDREW E. | KEPHERA DIAGNOSTICS, LLC, MA | $978,191 | ZRG1 |
| 2025 | Rapid 3D POC digital cancer pathology by unique confocal microscopy instrumentation and downstream AI: a simple, efficient, robust direct-to-digital approach to meet market demand1R44CA302122-01 | GAREAU, DANIEL SUMMERLAPRAD, ADAM | SURGIVANCE, INC., OR | $978,154 | ZRG1 |
| 2025 | Enhancing Dental and Craniomaxillofacial Surgery Outcomes with Cost-Effective and Scalable Animal-Free Amino Acid-Based Membranes for Guided Bone Regeneration1R44DE035026-01 | BOTTINO, MARCO CSOLIMAN, SHERIF | MATREGENIX, MA | $976,000 | ZRG1 |
| 2025 | Triage of Developmental and Reproductive Toxicants using an In vitro to In Vivo Extrapolation (IVIVE)-Toxicokinetic Computational modeling Application2R44ES035657-02A1 | ANTONIJEVIC, TODOR | SCITOVATION, LLC, NC | $973,277 | ZRG1 |
| 2025 | PhysioSim: Innovative Physiology Simulation Education Kits for Pre-College Students and Teachers1R44GM161237-01 | BECKER, ADAM | INNOVATIVE DESIGN LABS, INC., MN | $969,833 | ZGM1 |
| 2025 | Accurate Point of Care Liver Disease Diagnostics, Phase II2R44DK135225-02 · under PA-23-230 | PRADO, PABLO JSIRLIN, CLAUDE B | LIVIVOS INC., CA | $947,354 | ZRG1 |
| 2025 | A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents1R44HL180258-01 | SEKHON, UJJAL DIDAR SINGH | HAIMA THERAPEUTICS, LLC, OH | $944,676 | ZRG1 |
| 2025 | A Uniquely Scalable Platform for Sequencing Tens of Millions of Single Cells from Complex Clinical Samples with a Streamlined Workflow2R44GM149003-02 | SPUHLER, PHILIPP STEFAN | SANSIMEON, INC, CA | $938,335 | ZGM1 |
| 2025 | Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals1R44GM161364-01 | FRISCH, DAVID ALANDRY, CHARLES F | SCARAB GENOMICS, LLC, WI | $937,537 | ZGM1 |
| 2025 | Topical Eyedrops Increasing Lysyl Oxidase and Dopamine Activity to Control Myopia2R44EY034770-02 | MOLOKHIA, SARAH ABDULLA | IVEENA DELIVERY SYSTEMS, INC., UT | $933,817 | ZEY1 |
| 2025 | High-Resolution Direct-Conversion X-ray Detectors for Low-Dose Imaging1R44EB038123-01 | DATTA, AMLAN | CAPESYM, INC., MA | $925,411 | ZEB1 |
| 2025 | High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA2R44GM150317-02 | CHAMBERS, ROSS S | INTEGRAL MOLECULAR, PA | $923,143 | ZGM1 |
| 2025 | Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells2R44DK133008-02 | COHEN, DENA E | REGENERATIVE MEDICAL SOLUTIONS, INC., IL | $915,136 | ZRG1 |
| 2025 | Hydrogel injection molded islet macroencapsulation devices to treat diabetes in a non-human primate model2R44DK136496-02 | BECKER, MATTHEWKENYON, NORMA S. | IMMUNOSHIELD THERAPEUTICS INC., AZ | $913,868 | ZRG1 |
| 2025 | A point of care-device for the determination of creatinine phosphokinase (CPK), theCPK Now2R44HD114325-02A1 | HARPER, ROBERT | ANALYTICAL DIAGNOSTIC SOLUTIONS, INC., NJ | $906,002 | ZHD1 |
| 2025 | Development of a novel renalase agonist for the treatment of acute pancreatitis2R44DK111251-04 | DESIR, GARY V.LAINE, LOREN A.OHLSTEIN, ELIOT | BESSOR PHARMA, LLC, MA | $903,732 | ZRG1 |
| 2025 | Integrated Circuit Electrical DNA Assembly2R44GM150322-02 | HOLDEN, MATTHEW TAYLOR | AVERY BIO CORPORATION, CA | $894,545 | ZRG1 |
| 2025 | Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis2R44AI179391-02 | MALISKI, EDWARD G | OAK THERAPEUTICS, INC., KS | $892,787 | ZAI1 |
| 2025 | Biomarker discovery in colon cancer through next-generation metabolomics1R44CA295318-01A1 | STANCLIFFE, ETHAN | PANOME BIO INC, MO | $881,647 | ZRG1 |
| 2025 | Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 11R44EY037156-01 · under PA-23-230 | MOUILLESSEAUX, KEVIN P | ATSENA THERAPEUTICS, INC., NC | $870,675 | ZRG1 |
| 2025 | Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications1R44HL178134-01 · under PA-23-230 | CAHALAN, PATRICK THOMAS | ENSION, INC., PA | $870,467 | ZRG1 |
| 2025 | Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells1R44TR005945-01 | HAWLEY, BENJAMIN RICHARD | ENGAGE BIOLOGICS INC., CA | $865,162 | ZTR1 |
| 2025 | Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity1R44NS141534-01 · under PA-23-230 | SIMAO, FABRICIOZHANG, HONGKANG | QUIVER BIOSCIENCE INC., MA | $862,420 | ZRG1 |
| 2025 | Dialysate regeneration based on photo-electrochemical urea oxidation and reactive adsorption systems2R44DK137677-02A1 | FULKERSON, BARRY | KULEANA TECHNOLOGY, INC., WA | $853,604 | ZDK1 |
| 2025 | Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes2R44DK129875-04 · under PA-23-230 | TANGNEY, JARED RYLAN | BIOLINQ INCORPORATED, CA | $853,587 | ZRG1 |
| 2025 | Deep Immunophenotyping in tissue imaging1R44GM161324-01 | YU, JIANGBO | LAMPROGEN, INC., WA | $850,740 | ZGM1 |
| 2025 | Mucus and ALI Models of the Human Intestine2R44DK130708-02 · under PA-23-230 | BOAZAK, ELIZABETHSIMS, CHRISTOPHER ELDRIDGE | ALTIS BIOSYSTEMS, INC., NC | $835,939 | ZRG1 |
| 2025 | Low-Cost Platform Technology for Rapid Isolation of Peripheral Blood Mononuclear Cells2R44GM139391-02A1 · under PA-23-230 | HUANG, LOTIEN RICHARD | CG SCIENTIFIC, INC., MA | $833,381 | ZRG1 |
| 2025 | Smart Cavity Creator Drill for Lumbar Interbody Fusion: Direct to Phase II1R44AR085500-01 · under PA-23-230 | MIRZA, SOHAIL K | PEER TECHNOLOGIES, PLLC, DC | $830,712 | ZRG1 |
| 2025 | Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors2R44ES035550-02 | BEMIS, JEFFREY CDERTINGER, STEPHEN D | LITRON LABORATORIES, LTD., NY | $823,805 | ZES1 |
| 2025 | High Content Screening for Bifunctional Chimera Biologics1R44AI188872-01 · under PA-23-230 | VALENTE, LIZ | HELIGENICS INC, NV | $807,664 | ZRG1 |
| 2025 | A novel platform for nonribosomal peptide discovery1R44GM159545-01 | BEHSAZ, BAHAR | CHEMIA BIOSCIENCES, INC., PA | $781,502 | ZRG1 |
| 2025 | VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other solid tumors1R44CA291444-01A1 · under PA-23-230 | SHOWALTER, RICHARD EDWARD | VELORUM THERAPEUTICS INC., TX | $772,293 | ZRG1 |
| 2025 | Lung Cancer FAST (Fragment Analysis, SNP, and Translocations) Testing1R44CA306750-01 | BROWN, JUSTIN T | CEREUS DIAGNOSTICS CORP., TX | $764,448 | ZCA1 |
| 2025 | Dynamical Diffraction Analysis for 3D Electron Crystallography2R44GM148105-02 · under PA-23-230 | BROMBERG, RAQUEL | LIGO ANALYTICS, INC., TX | $762,936 | ZRG1 |
| 2025 | Performance evaluation of a non-invasive menstrual test for endometriosis in infertility patients1R44HD118899-01 | GIRE, STEPHEN | NEXTGENJANE, INC., CA | $759,944 | ZRG1 |
| 2025 | Evaluation of novel small molecule targeting lipid and energy homeostasis for treating obesity1R44DK142483-01A1 | IBRAHIM, PRABHA | RERX THERAPEUTICS, INC, CA | $752,158 | ZDK1 |
| 2025 | Automated Multiplex Analyzer for Sepsis and Beyond2R44GM146498-02 | KUNJAN, KISLAYA | CASCADE METRIX, LLC, IN | $720,920 | ZGM1 |
| 2025 | Real-time head motion monitoring for all clinical MR sequences using Universal FIRMM1R44AG097349-01 | KING, KEVIN | TURING MEDICAL TECHNOLOGIES INC, MO | $699,964 | ZAG1 |
| 2025 | Bioinformatics platform for large scale untargeted metabolomics analysis1R44GM162107-01 | EGAN, JOSEPH M | OMETA LABS LLC, CA | $675,609 | ZGM1 |
| 2025 | Smartphone based custom-fit and low-cost hearing aids manufacturing system1R44DC022803-01 | YI, STEVEN | XYKEN, LLC, VA | $673,350 | ZRG1 |
| 2025 | Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis1R44CA298064-01 · under PA-23-230 | GEORGE, TAD | RARECYTE, INC., WA | $658,336 | ZRG1 |
| 2025 | Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of Alzheimer's disease1R43AG097351-01 | SCHILB, ANDREW LORING | JANUSQ, LLC, OH | $576,664 | ZAG1 |
| 2025 | Next-generation Brillouin ocular scanner1R44EY036772-01A1 | BARNES, CLAIRE SHELLEYSCARCELLI, GIULIANO | INTELON OPTICS, INC., MA | $566,288 | ZRG1 |
| 2025 | Non-invasive brain stimulation using two-coil kTMP: simultaneous stimulation at two cortical targets and deep brain stimulation at a single target1R43MH143230-01 | LABRUNA, LUDOVICA | MAGNETIC TIDES, INC., CA | $557,588 | ZRG1 |
| 2025 | Auto-calibrating, Air Quality Monitoring System2R44OH012498-02 · under PA-23-230 | PATEL, SANJAY V | SEACOAST SCIENCE, INC., CA | $541,648 | ZRG1 |
| 2025 | Development of a multispecies live biotherapeutic product for the prevention of recurrent bacterial vaginosis1R44AI195248-01 | VALLADARES, RICARDO | SIOLTA THERAPEUTICS, INC., CA | $529,498 | ZAI1 |
| 2025 | Bioinspired Green Glycolipids as Fugitive Dust Mitigation Agents2R44ES034319-02 · under PA-23-230 | BOXLEY, CHETT J | GLYCOSURF, INC., UT | $511,412 | ZRG1 |
| 2025 | High bandwidth all-optical electrophysiology1R43MH139287-01 · under PA-23-230 | KILBORN, KARL | 3 I, CO | $505,311 | ZRG1 |
| 2025 | Title: New Clinical Biomarkers for GM1 Gamgliosidosis1R43NS139721-01A1 | BROWN, JILLIAN RGLASS, CHARLES ALEXANDER | TEGA THERAPEUTICS, INC., CA | $500,000 | ZRG1 |
Showing the 200 most recent of 7,961 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.